The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, considers key takeaways from the Impassion-131 clinical trial investigating first-line atezolizumab in combination with chemotherapy in metastatic triple-negative breast cancer (TNBC) presented at the 2020 ESMO Virtual Congress
Published: 01 October 2020
Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, discusses the final results of the Phase 3 ClarIDHy trial investigating ivosidenib in patients with previously treated IDH1-mutant cholangiocarcinoma as presented at the 2021 Gastrointestinal Cancers Symposium
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, considers the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, elaborates on the role of genetic testing in patients with cholangiocarcinoma (CCA)
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, offers opinion on ivosidenib as first-line therapy for patients with cholangiocarcinoma (CCA) and an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the 2021 ASCO Gastrointestinal Cancers Symposium
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the ...
Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, tells us about the results of the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Zev Wainberg, MD, discusses the safety profile of bemarituzumab
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, discusses the safety profile of bemarituzumab from the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, offers opinion on ivosidenib as first-line therapy for patients with cholangiocarcinoma (CCA) and an IDH1 mutation
Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, elaborates on the role of genetic testing in patients with cholangiocarcinoma (CCA)
Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, considers the potential impact of the ClarIDHy trial
Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, discusses the final results of the Phase 3 ClarIDHy trial investigating ivosidenib in patients with previously treated IDH1-mutant cholangiocarcinoma as presented at the 2021 Gastrointestinal Cancers Symposium
Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer
Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer and whether potential improvements in outcomes are on the horizon for this disease
Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, considers whether ctDNA testing informs targeted therapy choices for patients with gastric cancer
Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial
Dr. George, Director, GI Oncology Program, University of Florida, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial as presented at the 2021 Gastrointestinal Cancers Symposium
Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Zev Wainberg, MD, discusses the safety profile of bemarituzumab
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, discusses the safety profile of bemarituzumab from the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, tells us about the results of the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the 2021 ASCO Gastrointestinal Cancers Symposium
Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, elaborates on newly approved targeted therapies in esophagogastric cancer
Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, tells us about the NuTide:121 trial as presented at the 2021 Gastrointestinal Cancers Symposium
Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, considers how the progress of targeted therapies in GI cancer compares with progress seen in other tumor types
Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the most promising pathways for targeted therapies in hepatobiliary and esophagogastric cancers
Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, shares perspective on some of the newly approved targeted therapies in hepatobiliary cancer
Radhakrishnan Ramchandren, MD, offers opinion on the ECHELON-2 trial as presented at ASH 2020
Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, discusses the five-year follow-up of the ECHELON-2 study investigating brentuximab vedotin with chemotherapy in peripheral T-cell Lymphoma (PTCL) as presented at the 62nd ASH Annual Meeting & Exposition
Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotin
Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, provides perspective on the safety and efficacy of brentuximab vedotin in the management of Hodgkin Lymphoma and peripheral T-cell Lymphoma (PTCL) patients
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.